For example, 25% of breast cancer cases present with activated HER2 signaling, and trastuzumab (known as Herceptin), a humanized monoclonal antibody for HER2, is highly effective in HER2-positive breast cancer [3,4]. Here, ERBB2 is linked to breast carcinoma.